Email updates

Keep up to date with the latest news and content from Arthritis Research & Therapy and BioMed Central.

This article is part of the supplement: 23rd European Workshop for Rheumatology Research

Open Badges Meeting abstract

Analysis of the peptidylarginine deiminase V gene in rheumatoid arthritis

L Caponi1, E Petit-Teixeira3, M Sebbag2, F Bongiorni1, S Moscato1, F Pratesi1, J Osorio1, M Guerrin-Weber3, F Cornelis3, G Serre2, P Migliorini and European Consortium for Rheumatoid Arthritis Families (ECRAF)

Author Affiliations

1 Clinical Immunology Unit, University of Pisa, Pisa, Italy

2 INSERM U563, Toulouse, France

3 ECRAF and Genople EVRY, France

For all author emails, please log on.

Arthritis Res Ther 2003, 5(Suppl 1):3  doi:10.1186/ar633

The electronic version of this article is the complete one and can be found online at:

Published:24 February 2003


Meeting abstract

A number of rheumatoid arthritis (RA) sera contain antibodies specific for peptides in which arginine is substituted by the deiminated form citrulline (AKA). These antibodies are a marker of RA, as they are absent in other disorders. The enzyme responsible for the generation of citrulline residues, peptidylarginine deiminase (PAD), has different isoforms, with a specific tissue distribution. PAD V, expressed in monocytes, might be responsible for the deimination of arginine residues of synovial proteins and thus be involved in the generation of epitopes for RA-specific antibodies. The ECRAF genome scan showed suggestive linkage evidence at PAD V locus on chromosome 1 (P < 0.005). We decided to analyze PAD V as a candidate gene for RA, studying a cohort of 100 RA patients (tested for AKA) and their unaffected parents. Investigation (by single-strand conformation polymorphism [SSCP] analysis and sequencing) of the 16 exons, 5' and 3' regions of the PAD V gene provided polymorphisms in the 5', exons 3, 4, and 7 and 3' regions. Analysis used the transmission disequilibrium test and the haplotype relative risk for alleles and haplotypes with Analyze and Genhunter2 programs.

We found an association between RA and one PAD V haplotype (38% in RA versus 17% in controls) (P < 0.007). The association was also observed in the AKA+ RA subgroup (41%) (P < 0.03).

In conclusion, the PAD V gene may be considered one of the genetic factors that confer susceptibility to RA. Studies are in progress to clarify the relationship between the PAD V haplotypes, the enzyme activity and the production of anticitrulline antibodies.